Observing Bempedoic Acid and Ezetimibe Use in Adults with High Cholesterol
Observes real-world use of bempedoic acid, alone or with ezetimibe, in adults with high cholesterol.
Plain-language title generated from the registry record
Registry title: A Study of Bempedoic Acid or Its Single-pill Combination Therapy With Ezetimibe in Patients With Primary Hypercholesterolaemia or Mixed Dyslipidaemia
Key facts
- Where
- Hong Kong, Hong KongSee the 5 sites
Where in Hong Kong
- Princess Margaret HospitalHong Kong, Hong KongTaking people
- Queen Elizabeth HospitalHong Kong, Hong KongTaking people
- The Chinese University of Hong Kong-Prince of Wales Hospital (PWH)Hong Kong, Hong KongTaking people
- The University of Hong Kong (HKU)-Queen Mary Hospital (QMH)Hong Kong, Hong KongTaking people
- The University of Hong Kong/Queen Mary HospitalHong Kong, Hong KongTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Daiichi Sankyo
- Trial code
- NCT07206472
- Record updated
- 19 October 2026
- Original description
There is limited efficacy and safety data of bempedoic acid or its fixed dose combination (FDC) with ezetimibe in Asian and Latin American patients. This non-interventional study (NIS) will be conducted to characterize the risks and benefits of bempedoic acid or FDC with ezetimibe in a real-world clinical setting in adult patients with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia.Read full original descriptionShow less
A Multi-national, Non-interventional Study of Bempedoic Acid or Its Single-pill Combination Therapy With Ezetimibe in Routine Clinical Practice in Patients With Primary Hypercholesterolaemia or Mixed Dyslipidaemia
There is limited efficacy and safety data of bempedoic acid or its fixed dose combination (FDC) with ezetimibe in Asian and Latin American patients. This non-interventional study (NIS) will be conducted to characterize the risks and benefits of bempedoic acid or FDC with ezetimibe in a real-world clinical setting in adult patients with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia.
Patients can be enrolled, when they fulfil the following inclusion criteria:; Written informed consent to participate; At least 18 years of age; Patients suffering from documented primary hypercholesterolemia or mixed dyslipidaemia treated or intended to be treated with bempedoic acid/ FDC with ezetimibe at the discretion of the physician are appropriate for participation in the observation; For patients who are treated with bempedoic acid/FDC with ezetimibe prior to signed informed consent, initiation of bempedoic acid/FDC with ezetimibe must be within a maximum of three months prior to inclusion; No contraindications exist according to the SmPC of bempedoic acid/FDC with ezetimibe; No concurrent participation in an interventional study (simultaneous participation in other non-interventional study is possible); Life expectancy > 1 year; No explicit exclusion criteria exist to avoid selection bias and to allow for documentation of routine clinical practice.